Agility’s oncology-based technologies and services to expand in the US

Image Credit: Ricoh USA

Announcement

Agility, a known provider and manufacturer of medical device solutions to the US healthcare industry, has extended its advanced oncology offering to hospitals and physicians, with the highest value and availability to focal therapy services for treating and diagnosing prostate cancer. The HIFU and other focal therapy technologies enable urologists, oncologists, and physicians to proceed with the capability to accurately destroy and target the cancerous tissue while reducing the damage to the other healthy tissues.

This is described to support speedy recovery and reduce the risk of complications like erectile dysfunction and urinary incontinence, quicker in comparison to other treatment alternatives for prostate cancer. With the strong recognition and wide range of creative treatment alternatives, Agility has been a leading provider of the focal therapy technologies.

An extensive wave of technology with experienced, skilled certified technicians marks agility’s proficiency in enhancing the access and speed at which individuals can access the focal therapy technology and deliver robust prostate cancer care services for hospitals in treatment and diagnosis. Agility also offers a wave of complementary solutions for healthcare providers to begin with the focal therapy program in their practice.

Agility’s other strategic collaboration with known technology providers

The agility’s collaboration with Koelis, Sonablate, Varian, and Botimage AI is an impressive partnership to date. The Koelis is a known MRI integrated guidance manufacturer with its popular product Trinity, largely considered the most dynamic system for use in therapy and biopsy. It achieves peak accuracy and efficiency due to its exclusive 3D ultrasound and organ-related tracking technology. The partnership with Sonablate is an exclusive one that brings the region’s premier HIFU system to the vast Agility customers globally.

The Varian, a Siemens Healthineers company, was considered for the collaboration for microwave ablation and cryotherapy products, serving a variety of ablation technology treatment portfolios. The botimage AI’s prostatID platform is the one and only FDA-approved AI software for advanced prostate cancer identification, prostate cancer screening, and diagnosis.

Views and statements from the healthcare leaders

General manager of surgical technology services at Agility, Casey Branham, said, “There are around 313,000 new prostate cancer cases recorded every year in the US, and creative advanced technologies such as HIFU and other suitable focal therapies are an essential component of modern care. Agility is an excellent provider of on-demand technician services and surgical laser technology in the US, and we’re dedicated to serving our customers and their patients a massive range of surgical support alternatives engineered to promote effective, safe, and efficient outcomes in the OR.”